Keywords: Macular degeneration, Diabetic retinopathy, Visiongain, Kucentis, Roche, Eylea, Bayer, Regeneron
AMD and diabetic retinopathy drugs market to reach $5.08 billion by 2014, says Visiongain
Article | 11 July 2011
The market for age-related macular degeneration (AMD) and diabetic retinopathy (DR) drugs will reach over $5.08 billion by 2014. This will make ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
